Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
24 Results for "
issues
" in MedChemExpress (MCE) Product Catalog:
Products (24)
24 Results for "issues" in MCE Product Catalog:
33
33 Publications Verification
Synonyms: Ursodeoxycholate; Ursodiol; UDCA
33
33 Publications Verification
Synonyms: Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium
1
1 Cited Publications
Synonyms: Ursodeoxycholate-d4; Ursodiol-d4; UDCA-d4
Cat. No.: HY-B0326
CAS No.: 26750-81-2
Target:
Research Areas:
Alibendol can be taken orally. It has anti-spasmodic properties and promotes bile secretion, making it useful for research on digestive system issues like indigestion, nausea, vomiting, and constipation .
Cat. No.: HY-E70574
Target:
Research Areas:
Trypsin/Lys-C complex protease (MS grade) combines Trypsin and Lys-C, two recombinant proteases, to achieve efficient peptide bond hydrolysis. Trypsin specifically cleaves the C-terminal peptide bonds of arginine (R) and lysine (K), while Lys-C specifically cleaves the C-terminal peptide bonds of lysine (K). This combination overcomes issues such as the slower digestion rate of lysine and arginine by rTrypsin, PTM changes on lysine, or hydrophobic C-termini (such as proline) that can lead to missed cleavage. Trypsin/Lys-C complex protease (MS grade) can be used to process complex protein samples that are difficult to enzymatically digest. Trypsin/Lys-C complex protease (MS grade) can be used for protein characterization, single-cell proteomics and large cohort proteomics studies.
MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer .
Synonyms: Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)
Synonyms: SD-142
Target:
Research Areas:
EpoY (SD-142) acts as an irreversible inhibitor of the brain's primary tubulin tyrosine carboxypeptidase (TCP), a complex formed by vasohibin-1 (VASH1) and the small vasohibin binding protein (SVBP). By inhibiting TCP with an IC50 value of approximately 500 nM, EpoY effectively decreases levels of detyrosinated alpha-tubulin, which is crucial for microtubule dynamics and neuronal differentiation. This inhibition leads to significant differentiation defects and has been linked to underlying issues associated with cancer and cardiomyopathies.
Cat. No.: HY-13771S1
CAS No.: 63296-46-8
Synonyms: Ursodeoxycholate-13C; Ursodiol-13C; UDCA-13C
Cat. No.: HY-12629
CAS No.: 1539296-45-1
Synonyms: PF-06297470
PF470 (PF-06297470) is a negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) with significant efficacy in Parkinson's disease models, but clinical development was halted due to potential issues found in toxicology studies.
Tylocrebrine is a compound with anticancer activity. Its clinical research was interrupted due to toxicity issues. By making it into targeted nanoparticles, its inhibitory index can be improved, the killing effect on tumor cells can be enhanced and brain penetration can be reduced.
Cat. No.: HY-123649
CAS No.: 1246470-32-5
MK-4882 is an HCV NS5A inhibitor with activity in reducing viral load in a chimpanzee model of HCV infection, but with issues of viral breakthrough, prompting the development of compounds with greater potency against more genotypes and NS5A resistance mutations.
Cat. No.: HY-L030
760 compounds
The composition of endogenous metabolite compounds is affected by the upstream influence of the proteome and genome as well as environmental factors, lifestyle factors, medication, and underlying disease. Therefore, metabolites have been described as proximal reporters of disease because their abundances in biological specimens are often directly related to pathogenic mechanisms. In more recent years, metabolomics approach has been adopted or suggested to be used in various research areas including drug discovery, neurosciences, agriculture, food and nutrition, and environmental sciences.
MCE owns a unique collection of 760 human endogenous metabolites, all of which are derived from human issues. This library is a powerful tool for metabonomics research and metabolism-related drug discovery.
Cat. No.: HY-109194R
CAS No.: 1458063-04-1
Synonyms: REC 0559 (Standard)
Target:
Research Areas:
Udonitrectag (Standard) is the analytical standard of Udonitrectag (HY-109194). This product is intended for research and analytical applications. Udonitrectag (REC 0559), a low molecular weight compound that mimics NGF, aims to address the issue of NGF stability .
Cat. No.: HY-E0225
compounds
0.5 mL 96-Well Tube Rack, compliant with the industry-standard SBS (Society for Biomolecular Screening) specifications. This product features a sliding lock mechanism on the lid to prevent tube dislodgement. The side of the rack is equipped with an identifiable barcode for easy compound storage and retrieval. The matching tube (HY-E0224) is made from the same material as this tube, effectively preventing uneven expansion issues during freeze-thaw cycles.
Cat. No.: HY-L0124V
13,082 compounds
The basic requirements for the compounds that are supposed to penetrate the blood-brain barrier are somewhat different from those for the majority of drug discovery projects. Alongside the known problem with delivery of the large and non-polar compounds and their penetrability through the cell membrane, the other issue arises as well: small and polar compounds are not able to pass the Blood-Brain Barrier. Chemspace CNS-focused library comprises quite small, non-polar compounds that are also free from PAINS/toxic fragments and aggregators.
Cat. No.: HY-L141
2,924 compounds
Drug repurposing (also called drug repositioning, reprofiling, or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, for example, lower risk of failure, less investment, and shorter development timelines. But drug repositioning projects are also subject to several risks, including regulatory and intellectual property issues. So the off-patent drugs are optimal for repositioning because of their immediate availability for clinical studies, with high feasibility and relatively low risk.
MCE carefully prepared a unique collection of 2,924 off-patent drugs, which is a good choice for drug repurposing.
Cat. No.: HY-168168
CAS No.: 1544739-76-5
Target:
Research Areas:
(5aS,6R,6aR)-MK-8666 is a selective GPR40 agonist with activity in promoting fatty acid-induced insulin secretion in pancreatic β cells and intestinal enteroendocrine cells. (5aS,6R,6aR)-MK-8666 has been studied for the inhibition of type 2 diabetes and has shown significant blood glucose lowering effects. Although (5aS,6R,6aR)-MK-8666 is considered to have potential inhibitory advantages, its development was stopped in Phase I clinical trials due to liver safety issues .
Cat. No.: HY-E0224
compounds
0.5 mL Storage Tube, Three-Code Tube, External Thread with Screw Cap, Compatible with SBS- 96-Well Racks. This product is made from high-quality PP material, suitable for ultra-low temperature storage, with excellent weather resistance. Free from DNase and RNase, and can be sterilized by irradiation. The bottom of the tube features a unique QR code, while the side wall has a 1D linear barcode and directly readable numeric code, all three codes are identical and unique. The codes are laser-etched, scratch-resistant, not easy to fall off, and have high contrast for easy reading. The accompanying tube rack (HY-E0225) is made of the same material as the tube, effectively preventing uneven expansion issues during freeze-thaw cycles.
Cat. No.: HY-L102
1,904 compounds
Rare diseases are an important public-health issue and a challenge for the medical community. Most rare diseases are genetic disorders, which are often severely disabling, substantially affect life expectancy, and impair physical and mental abilities. Currently, there are about 7,000 identified rare diseases, together affecting 10% of the population. However, fewer than 6% of all rare diseases have an approved treatment option, highlighting their tremendous unmet needs in drug development. The process of repurposing drugs for new indications, compared with the development of novel orphan drugs, is a time-saving and cost-efficient method resulting in higher success rates, which can therefore drastically reduce the risk of drug development for rare diseases.
MCE carefully collects a unique of 1,904 compounds studied in preclinical, clinical trials or approved used in rare diseases treatment. MCE rare diseases drug library is a useful tool for the research of rare diseases. All compounds can provide corresponding indications for rare diseases.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
